Outcome of the Board of Directors Meeting held on Friday, August 14, 2026 is attached herewith.

237/LG/SE/AUG/2026/GBSL August 14, 2026 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code : 509079 Scrip Symbol : GUFICBIO Subject: Outcome of the Board of Directors Meeting held on Friday, August 14, 2026 Dear Sir/Madam, Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we wish to inform that the Board of Directors of the Company at its meeting held today, i.e. on Friday, August 14, 2026, inter-alia, considered and approved the following matters: 1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter ended June 30, 2026 along with the Limited Review Report thereon in terms of provisions of Regulation 33 of Listing Regulations. The copy of same is enclosed herewith as “Annexure A”. 2. Incorporation of a subsidiary in the Philippines and investment by way of subscription to the equity share capital of the proposed subsidiary, subject to completion of applicable statutory and regulatory formalities. The details required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed herewith as “Annexure B”. The meeting of the Board of Directors commenced at 5.00 p.m. and concluded at 6.10 p.m. Kindly take the same on your record. Thanking You, Yours truly, For Gufic Biosciences Limited Ami Shah Company Secretary & Compliance Officer Membership No. A39579 Encl.: As above Annexure A GUFBIICO SCIELNICMEIST ED Regd. KOaffmBiahclaeav: ait ny3 a7RIn,oIa a,nd d,S .A nNdh4e0r0i0 6(9E ast), Mumbai - (CLI2N4-100MH1984PLC033519) Web-swiwwt.eg ufiecm.-accioolrm p.ao lr@iaguotfinecsrbe,ilP oh.-6c07o22m26, F1 a-00x02 6027 261068 (Rs. in Lakhs except EPS) UnauSdtiatnedadan Cldoo nnseo SltiadtaoetFfmei ednn aRtne csifuaotllrhtQ esu aErtnedrJe ud3n 0e2, 0 26 Standalone Consolidated QuaErtnedre d Yeeanrd ed QuaErtnedre d Yeeanrd ed 1] Particulars No. 30-Ju3n1--2M6a3 r0--2J6u3 n1--2M5a3 r0--2J6u3 n1--2M6a3r0--2J6u3 n1--2M5a r-26 UnaudAiutdeidUt neadu dAiutdeidtU enda udAiutdeidUt neadu dAiutdeidt ed 1 Income aR evfernouopeme rations 26,08215.,82002 52.,26399 14.,10542 76.,50382 15.,81082 12.,93779 24.,2450 0.66 bO tihnecro me 45.7(151 9588 9.422 58.2415 .7(51 17.3972 .522 65.74 ToItnaclo me 26,12275.,50582 ,572.8605.9 5,3470 5.27,6142 7.2555, 062,442.6549.9 747, 666.40 2 Expenses aC oosmfta tecroinaslusm ed 10,61142.,24028 6,.895714 .25,85 4120.,36211 42.,24008 6,.895314 .25,85 42.32 bP urcoshfta oscek -in-trade 1,4038.9058. 14,44 266.,8427 31.,0480 3.80983 .1,4452 6.68,24 71.09 cC haniignne vse onffti onrgioisoewhdsoes rdp,rk g o-riaennss-dst ock-in-(5t1r7)a. d(3,8e110 5). 52152.(61,68 )9 5(5.1379). (13,8105). (5210)1 (.62,78)9 5.39 dE mplyeobee nepefnistes ex 4,1803,8.1449. 3,4579 9.1658, 1648,1.8008. 34,891 4.34,75 991,.156688 .08 eF inance cost 931.8944 3.7932 3.33,66 619.3114. 8944 3.7932 3.33,66 61.14 fD perecainaadtm ioortnie sxapteinosne 770.6716 4.8757 1.38,90 837.7240 .6716 4.87771 .839, 083.26 g Oetxhpeern ses 5,728.54,42 825.,8312 72.13,87 254,7.4.70770 5 ,151.5,6306 5.23,1908 1.00 ToEtpxaeln ses 2,13151 .23,3222.2,71165 2.88,5775 7.22,1342 3.26.1216 9.2503, 7387,60.1316. 50 3 ToPtrabolefi fetox prtceiei otnaeanmltds a(1 x-) 2 3,016.22,706 2.1,8692 7.87,05 483,0.0530. 29,849 5.10,67 278,.64514 .90 4 Exptcieiotneamls 5 ToPtraoBlfe ifTtoa rxe 3,016.22,706 2.1,8692 7.87,504 8.35,000 3.29,849 5.1,0762 7.84,615 4.90 6 Taexpxe nse Curtraexn t 608.0406 3.2252 2.10,307 0.2650 8.0406 3.2252 2.10,307 0.25 Deferred tax 162.1254 2.2109 8.3876 3.3186 4.6264 2.2109 8.3876 3.38 Sh(oErxtc)l/e apsrxso visiyeoanr so f earlier ToTtaaxlpe nEsxes 770.1750 5.4452 0.23,273 3.6737 2.6760 5.4452 0.23,273 3.63 7 NePtr offotirhpet er firocodom n tgoi penruaitnions 2,246.20,055 7.1,4240 7.63,331 4.28,273 1.22,188 9.1,6310 7.60,442 1.27 Lesso:Pf r So(hLfiao)trts /ers antsof eyMrI irnnetoder rietst - - (0.)2 0 8 ToPtraoflfo peirrt i od 2,2456 .20,057.1,4240 7.63,331 4.28,273 1.22,188 9.16,310 7.60,442 1.47 9 OthCeorm preIhnecn(OosCm)iIe v e a)Ittehmwasint lob ltre e cltaPosr sooirff iiLteo ds s 66.72 66.72 66.72 66.72 LeIsnsc:to armxee gl t aiott itenhmwasint lob eltr ecltaPosr sooiLrffo iistes d (16.)7 9 (1.697) (16). 79 (16). 79 b)Ittehmwasibt lre le cltaos soPiLrrfiso oesfidt 10.03 LeIsnsc:to armxee gl t aiott itenhmwasibt le l reclaosLrso isfsied to Profit (2.)5 1 Otheprre hCeoInmnsciLovom(ense es/ott fa )xes 49.93 49.93 7.53 49.93 49.93 10 ToCtoapmrle heInnsciovmee 2,246.02,510 7.1,3270 7.63,3634 .82,203 8.28,213 9.1,5340 7.60,447 1.40 11 Othqueyi R tEeserves 6,4515.42 6,459023. 12 Detoafqiu liESsth yaC raep ital Paipedq u-yisu thcapariet al 1,002.18,030 2.1,8030 2.71,080 2.18,030 2.18,030 2.18,30 021,.07082 .83 Favcaeol fuqu tyeise hacpraiet(R as)l. 1.00 1.00 1.00 1.00 100 1.00 1.00 1.00 13 Eargpn eieqruny is thare Baesaigrcspn e isrnh arceo nfgtra iondnmdiu sicnopenrtaitniuoends o i 2.24 2.05 1.20 6.30 2.22 2.18 1.30 6.40 iiD ileuaintgrsepne dr shcaornegt a infdndriu osimcn oopnetriantuieodn s 2.24 2.05 1.20 6.30 2.22 2.18 1.30 6.40 2] Notes: 1. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder. 2. The above results for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 14, 2026. The Statutory Auditors have carried out limited review of the results for quarter ended June 30, 2026. 3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals. 4. The equity shares and basic/diluted earnings per share has been presented in accordance with Ind AS -33-Earning per share. 5. The figures for the quarter ended March 31, 2026 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to -date figures up to the third quarter ended December 31, 2025 which were subjected to limited review. 6. Previous year/quarters figures have been regrouped/reclassified, wherever necessary. FOR GUFIC BIOSCIENCES LIMITED PRANAV J. CHOKSI CEO & WHOLE TIME DIRECTOR DIN: 00001731 PLACE : MUMBAI DATE : 14/08/2026 00 MITTAL AGARWAL & COMPANY CHARTERED ACCOUNTANTS Limited Review Report on the Standalone Unaudited Quarterly Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Gufic Biosciences Limited 1) We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Gufic Biosciences Limited (the "Company") for the quarter ended 30 June 2026 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2) This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review. 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by [Showing first 8,000 characters — download PDF for full document]